BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other...

Descripción completa

Detalles Bibliográficos
Autores principales: Poussard, Margaux, Philippe, Laure, Fredon, Maxime, Bôle‐Richard, Elodie, Biichle, Sabeha, Renosi, Florian, Perrin, Sophie, Kroemer, Marie, Limat, Samuel, Bonnefoy, Francis, Daguindau, Etienne, Deconinck, Eric, Gruson, Bérengère, Saas, Philippe, Adotévi, Olivier, Garnache‐Ottou, Francine, Angelot‐Delettre, Fanny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176134/
https://www.ncbi.nlm.nih.gov/pubmed/35846081
http://dx.doi.org/10.1002/jha2.149
_version_ 1784722597948162048
author Poussard, Margaux
Philippe, Laure
Fredon, Maxime
Bôle‐Richard, Elodie
Biichle, Sabeha
Renosi, Florian
Perrin, Sophie
Kroemer, Marie
Limat, Samuel
Bonnefoy, Francis
Daguindau, Etienne
Deconinck, Eric
Gruson, Bérengère
Saas, Philippe
Adotévi, Olivier
Garnache‐Ottou, Francine
Angelot‐Delettre, Fanny
author_facet Poussard, Margaux
Philippe, Laure
Fredon, Maxime
Bôle‐Richard, Elodie
Biichle, Sabeha
Renosi, Florian
Perrin, Sophie
Kroemer, Marie
Limat, Samuel
Bonnefoy, Francis
Daguindau, Etienne
Deconinck, Eric
Gruson, Bérengère
Saas, Philippe
Adotévi, Olivier
Garnache‐Ottou, Francine
Angelot‐Delettre, Fanny
author_sort Poussard, Margaux
collection PubMed
description Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored. We set up a model to test the combination of polychemotherapy ‐ named methotrexate, idarubicine, dexamethasone, and L‐asparaginase (MIDA) ‐ and CD123 CAR‐T cell therapy. We showed that CD123 CAR‐T cells exert the same effect on BPDCN models alone, or after MIDA regimen. These data support a preclinical rationale to use immunotherapy after a treatment with polychemotherapy for BPDCN patients.
format Online
Article
Text
id pubmed-9176134
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91761342022-07-14 BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity Poussard, Margaux Philippe, Laure Fredon, Maxime Bôle‐Richard, Elodie Biichle, Sabeha Renosi, Florian Perrin, Sophie Kroemer, Marie Limat, Samuel Bonnefoy, Francis Daguindau, Etienne Deconinck, Eric Gruson, Bérengère Saas, Philippe Adotévi, Olivier Garnache‐Ottou, Francine Angelot‐Delettre, Fanny EJHaem Case Reports Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored. We set up a model to test the combination of polychemotherapy ‐ named methotrexate, idarubicine, dexamethasone, and L‐asparaginase (MIDA) ‐ and CD123 CAR‐T cell therapy. We showed that CD123 CAR‐T cells exert the same effect on BPDCN models alone, or after MIDA regimen. These data support a preclinical rationale to use immunotherapy after a treatment with polychemotherapy for BPDCN patients. John Wiley and Sons Inc. 2020-12-13 /pmc/articles/PMC9176134/ /pubmed/35846081 http://dx.doi.org/10.1002/jha2.149 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Poussard, Margaux
Philippe, Laure
Fredon, Maxime
Bôle‐Richard, Elodie
Biichle, Sabeha
Renosi, Florian
Perrin, Sophie
Kroemer, Marie
Limat, Samuel
Bonnefoy, Francis
Daguindau, Etienne
Deconinck, Eric
Gruson, Bérengère
Saas, Philippe
Adotévi, Olivier
Garnache‐Ottou, Francine
Angelot‐Delettre, Fanny
BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
title BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
title_full BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
title_fullStr BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
title_full_unstemmed BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
title_short BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
title_sort bpdcn: when polychemotherapy does not compromise allogeneic cd123 car‐t cell cytotoxicity
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176134/
https://www.ncbi.nlm.nih.gov/pubmed/35846081
http://dx.doi.org/10.1002/jha2.149
work_keys_str_mv AT poussardmargaux bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT philippelaure bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT fredonmaxime bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT bolerichardelodie bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT biichlesabeha bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT renosiflorian bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT perrinsophie bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT kroemermarie bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT limatsamuel bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT bonnefoyfrancis bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT daguindauetienne bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT deconinckeric bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT grusonberengere bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT saasphilippe bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT adoteviolivier bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT garnacheottoufrancine bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity
AT angelotdelettrefanny bpdcnwhenpolychemotherapydoesnotcompromiseallogeneiccd123cartcellcytotoxicity

Ejemplares similares